Related Experiment Video

Updated: Apr 21, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.8K

Longitudinal dynamics of fasting plasma uridine in the preclinical stage of type 1 diabetes

Qiutang Xiong1, Chelsea Jang1, Kevin Wang1

  • 1Department of Diabetes and Cancer Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA.

Journal of the Endocrine Society
|April 20, 2026
PubMed

Insights

Plasma uridine levels increase around the onset of type 1 diabetes (T1D) in at-risk individuals. These changes in uridine may serve as an early biomarker for T1D development.

Area of Science:

  • Metabolomics
  • Biomarker Discovery
  • Endocrinology

Background:

  • Elevated blood uridine levels are observed in children with new-onset type 1 diabetes (T1D).
  • The significance of these uridine levels in relation to T1D onset is not fully understood.

Purpose of the Study:

  • To investigate the association between plasma uridine changes and the development of T1D in individuals at risk.
  • To determine if uridine levels can predict T1D onset.

Main Methods:

  • Analysis of plasma uridine concentrations using LC-MS/MS in pre- and post-T1D onset samples from the Diabetes Prevention Trial-Type 1.
  • Exclusion of participants with confounding factors like obesity or insulin resistance.
  • Matched case-control analysis of 23 pairs to assess uridine levels and T1D risk.

Main Results:

  • Individuals who developed T1D showed increased plasma uridine around diagnosis (P = .001).
  • Controls demonstrated a decrease in plasma uridine over time (P < .001).
  • Baseline fasting uridine levels showed discriminatory performance for T1D (AUC = 0.773), with significant time × group interaction observed.

Conclusions:

  • Fasting uridine level dynamics appear to precede T1D onset.
  • Plasma uridine may function as a predictive biomarker for type 1 diabetes.
Abstract

Keywords:
DPT-1 studyfasting uridineonset of type 1 diabetestype 1 diabetes

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.2K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.8K

Related Concept Videos

Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
9
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
2
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
4
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
6
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
2
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
2